BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 36831552)

  • 1. Association between Tumor Mutational Burden, Stromal CD8
    Ruan H; Oike T; Sato H; Ando K; Ohno T
    Cancers (Basel); 2023 Feb; 15(4):. PubMed ID: 36831552
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genomic landscape and its correlations with tumor mutational burden, PD-L1 expression, and immune cells infiltration in Chinese lung squamous cell carcinoma.
    Jiang T; Shi J; Dong Z; Hou L; Zhao C; Li X; Mao B; Zhu W; Guo X; Zhang H; He J; Chen X; Su C; Ren S; Wu C; Zhou C
    J Hematol Oncol; 2019 Jul; 12(1):75. PubMed ID: 31299995
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High tumor mutational burden predicts worse prognosis for cervical cancer treated with radiotherapy.
    Ota N; Yoshimoto Y; Darwis NDM; Sato H; Ando K; Oike T; Ohno T
    Jpn J Radiol; 2022 May; 40(5):534-541. PubMed ID: 34860358
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Automated Quantitative CD8+ Tumor-Infiltrating Lymphocytes and Tumor Mutation Burden as Independent Biomarkers in Melanoma Patients Receiving Front-Line Anti-PD-1 Immunotherapy.
    Fortman D; Karunamurthy A; Hartman D; Wang H; Seigh L; Abukhiran I; Najjar YG; Pantanowitz L; Zarour HM; Kirkwood JM; Davar D
    Oncologist; 2024 Apr; ():. PubMed ID: 38655867
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessment of associations between clinical and immune microenvironmental factors and tumor mutation burden in resected nonsmall cell lung cancer by applying machine learning to whole-slide images.
    Ono A; Terada Y; Kawata T; Serizawa M; Isaka M; Kawabata T; Imai T; Mori K; Muramatsu K; Hayashi I; Kenmotsu H; Ohshima K; Urakami K; Nagashima T; Kusuhara M; Akiyama Y; Sugino T; Ohde Y; Yamaguchi K; Takahashi T
    Cancer Med; 2020 Jul; 9(13):4864-4875. PubMed ID: 32400056
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor mutational burden and immune infiltrates in renal cell carcinoma and matched brain metastases.
    Steindl A; Alpar D; Heller G; Mair MJ; Gatterbauer B; Dieckmann K; Widhalm G; Hainfellner JA; Schmidinger M; Bock C; Müllauer L; Preusser M; Berghoff AS
    ESMO Open; 2021 Apr; 6(2):100057. PubMed ID: 33588158
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Qualitative Analysis of Tumor-Infiltrating Lymphocytes across Human Tumor Types Reveals a Higher Proportion of Bystander CD8
    Gokuldass A; Draghi A; Papp K; Borch TH; Nielsen M; Westergaard MCW; Andersen R; Schina A; Bol KF; Chamberlain CA; Presti M; Met Ö; Harbst K; Lauss M; Soraggi S; Csabai I; Szállási Z; Jönsson G; Svane IM; Donia M
    Cancers (Basel); 2020 Nov; 12(11):. PubMed ID: 33198174
    [No Abstract]   [Full Text] [Related]  

  • 8. Prognostic value of the density of tumor-infiltrating lymphocytes in colorectal cancer liver metastases.
    Wang E; Shibutani M; Nagahara H; Fukuoka T; Iseki Y; Okazaki Y; Kashiwagi S; Tanaka H; Maeda K
    Oncol Lett; 2021 Dec; 22(6):837. PubMed ID: 34712361
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Paired primary and metastatic lesions of patients with ipilimumab-treated melanoma: high variation in lymphocyte infiltration and HLA-ABC expression whereas tumor mutational load is similar and correlates with clinical outcome.
    Gorris MAJ; van der Woude LL; Kroeze LI; Bol K; Verrijp K; Amir AL; Meek J; Textor J; Figdor CG; de Vries IJM
    J Immunother Cancer; 2022 May; 10(5):. PubMed ID: 35550553
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinicopathological Features, Tumor Mutational Burden, and Tumour-Infiltrating Lymphocyte Interplay in
    Uchida S; Kojima T; Sugino T
    Pathol Oncol Res; 2021; 27():633243. PubMed ID: 34257600
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Deciphering Microenvironment of NSCLC based on CD8+ TIL Density and PD-1/PD-L1 Expression.
    Lin Z; Gu J; Cui X; Huang L; Li S; Feng J; Liu B; Zhou Y
    J Cancer; 2019; 10(1):211-222. PubMed ID: 30662542
    [No Abstract]   [Full Text] [Related]  

  • 12. High intratumoral CD8
    Yang Y; Attwood K; Bshara W; Mohler JL; Guru K; Xu B; Kalinski P; Chatta G
    Prostate; 2021 Jan; 81(1):20-28. PubMed ID: 33085799
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Theragnostic significance of tumor-infiltrating lymphocytes and Ki67 in BRAFV600-mutant metastatic melanoma (BRIM-3 trial).
    Googe PB; Theocharis S; Pergaris A; Li H; Yan Y; McKenna EF; Moschos SJ
    Curr Probl Cancer; 2022 Jun; 46(3):100862. PubMed ID: 35398635
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Changes and prognostic values of tumor-infiltrating lymphocyte subsets after primary systemic therapy in breast cancer.
    Ahn S; Chung YR; Seo AN; Kim M; Woo JW; Park SY
    PLoS One; 2020; 15(5):e0233037. PubMed ID: 32401825
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical Activity of an hTERT-Specific Cancer Vaccine (Vx-001) in "Immune Desert" NSCLC.
    Pateras IS; Kotsakis A; Avgeris M; Baliou E; Kouroupakis P; Patsea E; Georgoulias V; Menez-Jamet J; Kinet JP; Kosmatopoulos K
    Cancers (Basel); 2021 Apr; 13(7):. PubMed ID: 33916194
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumor-infiltrating B cells affect the progression of oropharyngeal squamous cell carcinoma via cell-to-cell interactions with CD8
    Hladíková K; Koucký V; Bouček J; Laco J; Grega M; Hodek M; Zábrodský M; Vošmik M; Rozkošová K; Vošmiková H; Čelakovský P; Chrobok V; Ryška A; Špíšek R; Fialová A
    J Immunother Cancer; 2019 Oct; 7(1):261. PubMed ID: 31623665
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The tumor immune microenvironment and its implications for clinical outcome in patients with oropharyngeal squamous cell carcinoma.
    Gurin D; Slavik M; Hermanova M; Selingerova I; Kazda T; Hendrych M; Shatokhina T; Vesela M
    J Oral Pathol Med; 2020 Oct; 49(9):886-896. PubMed ID: 32516834
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of Genomic Instability Score, Tumor Mutational Burden, and Tumor-Infiltrating Lymphocytes as Biomarkers in Uterine Serous Carcinoma.
    Bloom EA; Peters PN; Whitaker R; Russell S; Albright B; Cummings S; Timms KM; Slavin T; Probst B; Strickland KC; Previs RA
    Cancers (Basel); 2023 Jan; 15(2):. PubMed ID: 36672477
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor Infiltrating Lymphocyte Expression of PD-1 Predicts Response to Anti-PD-1/PD-L1 Immunotherapy.
    Bevins NJ; Okamura R; Montesion M; Adashek JJ; Goodman AM; Kurzrock R
    J Immunother Precis Oncol; 2022 Nov; 5(4):90-97. PubMed ID: 36483582
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Distinct mutational profile and immune microenvironment in microsatellite-unstable and
    Hwang HS; Kim D; Choi J
    J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34607897
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.